Physician profile
Sandra Reiners
NPI 1356503759
$1,245.58
in general payments reported to CMS, 2019-2025
18 companies · $540 in 2025
The $540 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $69.91 · 2022: $46.85 · 2023: $185 · 2024: $404 · 2025: $540.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,128.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $236.77 | 2024-2025 | Dupixent |
| Genzyme Corporation | $162.66 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $119.87 | 2022-2024 | Farxiga, Fasenra, Tezspire |
| Pfizer INC. | $97.16 | 2023-2024 | |
| Abbvie INC. | $77.61 | 2022-2025 | |
| Inari Medical, INC. | $69.91 | 2021 | |
| Boston Scientific Corporation | $69.30 | 2023 | Resonate El Icd Vr |
| Vanda Pharmaceuticals INC. | $61.64 | 2025 | Fanapt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $55.00 | 2025 | Caplyta |
| Hikma Pharmaceuticals USA | $54.98 | 2023-2024 | Ryaltris |
| Glaxosmithkline, LLC. | $52.63 | 2024-2025 | Nucala |
| Organon LLC | $44.64 | 2025 | Nexplanon |
| Lilly USA, LLC | $39.80 | 2025 | Zepbound, Mounjaro |
| Novo Nordisk INC | $32.38 | 2024 | Ozempic, Rybelsus |
| Optinose US, INC. | $19.28 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $18.69 | 2025 | Nuzyra, Xhance |
| Axsome Therapeutics, INC. | $18.55 | 2025 | Auvelity |
| Amgen INC. | $14.71 | 2024 | Otezla, Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Reiners listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.